Concepts (264)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Papillomavirus Vaccines | 10 | 2018 | 405 | 2.25 | Why? |
| Immunization Programs | 17 | 2021 | 2006 | 2.00 | Why? |
| Cost-Benefit Analysis | 18 | 2021 | 2259 | 1.82 | Why? |
| Papillomavirus Infections | 10 | 2018 | 861 | 1.80 | Why? |
| Papillomaviridae | 4 | 2018 | 404 | 1.26 | Why? |
| Measles | 5 | 2021 | 608 | 1.25 | Why? |
| Bacterial Vaccines | 3 | 2021 | 139 | 1.01 | Why? |
| Pneumococcal Vaccines | 3 | 2019 | 571 | 0.96 | Why? |
| Inflation, Economic | 1 | 2019 | 13 | 0.81 | Why? |
| Models, Statistical | 9 | 2020 | 5312 | 0.80 | Why? |
| Vaccination | 22 | 2021 | 19050 | 0.77 | Why? |
| Economics, Medical | 1 | 2019 | 35 | 0.76 | Why? |
| Vaginal Neoplasms | 1 | 2018 | 39 | 0.76 | Why? |
| Vulvar Neoplasms | 1 | 2018 | 59 | 0.74 | Why? |
| Condylomata Acuminata | 1 | 2018 | 62 | 0.73 | Why? |
| Rotavirus Vaccines | 2 | 2018 | 203 | 0.73 | Why? |
| Yellow Fever | 1 | 2021 | 231 | 0.72 | Why? |
| Meningococcal Infections | 1 | 2021 | 216 | 0.71 | Why? |
| Penile Neoplasms | 1 | 2018 | 97 | 0.68 | Why? |
| Costs and Cost Analysis | 3 | 2020 | 694 | 0.67 | Why? |
| Anus Neoplasms | 1 | 2018 | 123 | 0.65 | Why? |
| Disease Notification | 1 | 2020 | 639 | 0.53 | Why? |
| Uterine Cervical Neoplasms | 3 | 2018 | 842 | 0.51 | Why? |
| Measles Vaccine | 3 | 2021 | 301 | 0.49 | Why? |
| Mass Vaccination | 3 | 2018 | 1101 | 0.48 | Why? |
| Models, Theoretical | 12 | 2021 | 6659 | 0.48 | Why? |
| Health Expenditures | 2 | 2019 | 904 | 0.47 | Why? |
| Health Care Costs | 4 | 2018 | 1007 | 0.47 | Why? |
| Streptococcus pneumoniae | 1 | 2017 | 827 | 0.45 | Why? |
| Pneumococcal Infections | 2 | 2018 | 562 | 0.44 | Why? |
| Communicable Diseases | 2 | 2017 | 2148 | 0.44 | Why? |
| Social Behavior | 1 | 2017 | 882 | 0.37 | Why? |
| Models, Biological | 4 | 2021 | 4907 | 0.35 | Why? |
| Bacterial Infections | 2 | 2021 | 2229 | 0.35 | Why? |
| Homosexuality, Male | 1 | 2017 | 1158 | 0.35 | Why? |
| Bacteria | 1 | 2017 | 1897 | 0.32 | Why? |
| Decision Making | 4 | 2019 | 3132 | 0.30 | Why? |
| Head and Neck Neoplasms | 1 | 2018 | 1568 | 0.30 | Why? |
| Health Policy | 5 | 2020 | 6242 | 0.30 | Why? |
| Vaccines, Conjugate | 2 | 2019 | 328 | 0.30 | Why? |
| Schools | 1 | 2021 | 4187 | 0.28 | Why? |
| Child, Preschool | 16 | 2021 | 36283 | 0.28 | Why? |
| England | 8 | 2021 | 5116 | 0.28 | Why? |
| Mobile Health Units | 1 | 2011 | 741 | 0.27 | Why? |
| Infant | 12 | 2021 | 30274 | 0.27 | Why? |
| Patient Admission | 2 | 2021 | 5250 | 0.27 | Why? |
| Rotavirus Infections | 2 | 2018 | 355 | 0.26 | Why? |
| Quality-Adjusted Life Years | 4 | 2021 | 511 | 0.25 | Why? |
| Gastroenteritis | 2 | 2018 | 489 | 0.24 | Why? |
| Travel | 2 | 2020 | 7220 | 0.24 | Why? |
| Immunization Schedule | 3 | 2020 | 1305 | 0.23 | Why? |
| Models, Economic | 3 | 2021 | 316 | 0.23 | Why? |
| Ships | 1 | 2020 | 1046 | 0.23 | Why? |
| Global Health | 7 | 2021 | 13911 | 0.23 | Why? |
| Vaccines | 6 | 2021 | 3692 | 0.23 | Why? |
| Child | 17 | 2021 | 70012 | 0.23 | Why? |
| Empirical Research | 1 | 2021 | 72 | 0.22 | Why? |
| Contact Tracing | 2 | 2021 | 8448 | 0.22 | Why? |
| Disease Outbreaks | 5 | 2021 | 27595 | 0.22 | Why? |
| Humans | 67 | 2021 | 930598 | 0.22 | Why? |
| Tuberculosis, Pulmonary | 1 | 2011 | 1171 | 0.22 | Why? |
| Safety-Based Drug Withdrawals | 1 | 2020 | 52 | 0.21 | Why? |
| Immunization | 3 | 2020 | 2019 | 0.21 | Why? |
| Burkina Faso | 1 | 2021 | 302 | 0.21 | Why? |
| Advisory Committees | 2 | 2018 | 1418 | 0.21 | Why? |
| Respiratory Tract Infections | 2 | 2018 | 6817 | 0.21 | Why? |
| Developing Countries | 7 | 2019 | 4283 | 0.19 | Why? |
| Yellow Fever Vaccine | 1 | 2021 | 198 | 0.19 | Why? |
| Podophyllotoxin | 1 | 2018 | 22 | 0.19 | Why? |
| Incidence | 6 | 2020 | 25622 | 0.19 | Why? |
| Genital Diseases, Male | 1 | 2018 | 28 | 0.19 | Why? |
| Adolescent | 17 | 2021 | 86841 | 0.19 | Why? |
| Anti-Bacterial Agents | 2 | 2018 | 10083 | 0.19 | Why? |
| Cost of Illness | 3 | 2020 | 1903 | 0.19 | Why? |
| Pneumonia | 1 | 2019 | 5652 | 0.19 | Why? |
| Resource Allocation | 2 | 2021 | 1771 | 0.18 | Why? |
| Anus Diseases | 1 | 2018 | 55 | 0.18 | Why? |
| Meningococcal Vaccines | 1 | 2021 | 225 | 0.18 | Why? |
| Sexual Behavior | 2 | 2018 | 1322 | 0.18 | Why? |
| Police | 1 | 2021 | 243 | 0.18 | Why? |
| Epidemics | 5 | 2020 | 6407 | 0.17 | Why? |
| Genital Diseases, Female | 1 | 2018 | 110 | 0.17 | Why? |
| Mongolia | 1 | 2017 | 33 | 0.17 | Why? |
| Asymptomatic Diseases | 1 | 2020 | 3444 | 0.17 | Why? |
| Health Equity | 2 | 2021 | 1223 | 0.17 | Why? |
| Human papillomavirus 16 | 1 | 2017 | 95 | 0.16 | Why? |
| Ethiopia | 1 | 2021 | 1222 | 0.16 | Why? |
| Investments | 1 | 2019 | 166 | 0.16 | Why? |
| Health Personnel | 3 | 2021 | 29646 | 0.16 | Why? |
| Infant, Newborn | 5 | 2021 | 23105 | 0.16 | Why? |
| Quality Control | 1 | 2020 | 628 | 0.16 | Why? |
| Severe Acute Respiratory Syndrome | 1 | 2020 | 12361 | 0.16 | Why? |
| Critical Care | 1 | 2020 | 14081 | 0.16 | Why? |
| Hand, Foot and Mouth Disease | 1 | 2017 | 115 | 0.15 | Why? |
| Health Facility Closure | 1 | 2017 | 111 | 0.15 | Why? |
| Budgets | 1 | 2018 | 155 | 0.15 | Why? |
| Young Adult | 14 | 2021 | 93724 | 0.15 | Why? |
| Severe Dengue | 1 | 2017 | 135 | 0.15 | Why? |
| Population Density | 1 | 2021 | 694 | 0.15 | Why? |
| Antigens | 1 | 2017 | 267 | 0.15 | Why? |
| Quality of Life | 4 | 2018 | 9820 | 0.15 | Why? |
| Bangladesh | 1 | 2021 | 1620 | 0.14 | Why? |
| Africa | 2 | 2021 | 2986 | 0.14 | Why? |
| Geography | 1 | 2021 | 1801 | 0.14 | Why? |
| Gonorrhea | 1 | 2018 | 315 | 0.14 | Why? |
| Age Distribution | 2 | 2021 | 3567 | 0.14 | Why? |
| Bed Occupancy | 1 | 2018 | 476 | 0.14 | Why? |
| Europe | 3 | 2021 | 12702 | 0.14 | Why? |
| Drug Resistance, Microbial | 1 | 2018 | 419 | 0.14 | Why? |
| Medical Staff | 1 | 2020 | 723 | 0.13 | Why? |
| Pandemics | 20 | 2021 | 389249 | 0.13 | Why? |
| Female | 25 | 2021 | 380317 | 0.13 | Why? |
| Demography | 2 | 2017 | 1660 | 0.13 | Why? |
| Quarantine | 1 | 2021 | 18418 | 0.13 | Why? |
| Malaysia | 1 | 2018 | 1116 | 0.13 | Why? |
| Communicable Disease Control | 7 | 2021 | 29620 | 0.13 | Why? |
| Portugal | 1 | 2018 | 1265 | 0.12 | Why? |
| Immunity, Herd | 2 | 2021 | 1011 | 0.12 | Why? |
| Brazil | 2 | 2021 | 12582 | 0.12 | Why? |
| Communicable Diseases, Imported | 1 | 2020 | 843 | 0.12 | Why? |
| Drug Industry | 1 | 2020 | 689 | 0.12 | Why? |
| Vaccination Coverage | 2 | 2021 | 1249 | 0.12 | Why? |
| Poverty | 2 | 2021 | 2302 | 0.11 | Why? |
| Male | 21 | 2021 | 367725 | 0.11 | Why? |
| Pneumonia, Viral | 9 | 2020 | 243684 | 0.11 | Why? |
| Observation | 1 | 2011 | 80 | 0.11 | Why? |
| Adult | 17 | 2021 | 244371 | 0.11 | Why? |
| Population Surveillance | 2 | 2020 | 4967 | 0.11 | Why? |
| Coronavirus Infections | 9 | 2020 | 253789 | 0.11 | Why? |
| Public Opinion | 1 | 2021 | 1165 | 0.11 | Why? |
| Urban Population | 1 | 2021 | 2000 | 0.11 | Why? |
| Drug Approval | 1 | 2020 | 1325 | 0.11 | Why? |
| Coronavirus | 1 | 2020 | 18339 | 0.11 | Why? |
| Immunization, Secondary | 1 | 2018 | 1649 | 0.10 | Why? |
| United Kingdom | 5 | 2021 | 18046 | 0.10 | Why? |
| Vietnam | 1 | 2015 | 1665 | 0.10 | Why? |
| Trust | 1 | 2020 | 1487 | 0.10 | Why? |
| Epidemiological Monitoring | 2 | 2020 | 3493 | 0.10 | Why? |
| Calibration | 1 | 2020 | 307 | 0.10 | Why? |
| Interpersonal Relations | 1 | 2017 | 926 | 0.10 | Why? |
| Rural Population | 1 | 2021 | 2408 | 0.09 | Why? |
| Prevalence | 6 | 2020 | 25773 | 0.09 | Why? |
| Seasons | 2 | 2018 | 4071 | 0.09 | Why? |
| Caregivers | 2 | 2020 | 3112 | 0.09 | Why? |
| Cities | 1 | 2020 | 4937 | 0.09 | Why? |
| Drug Resistance, Bacterial | 1 | 2017 | 1414 | 0.09 | Why? |
| Internationality | 1 | 2020 | 3297 | 0.09 | Why? |
| International Cooperation | 1 | 2021 | 3436 | 0.08 | Why? |
| Influenza Vaccines | 2 | 2021 | 2941 | 0.08 | Why? |
| Workflow | 1 | 2017 | 2373 | 0.08 | Why? |
| Aged, 80 and over | 7 | 2021 | 88759 | 0.08 | Why? |
| Family Characteristics | 1 | 2017 | 2551 | 0.08 | Why? |
| Cross Infection | 2 | 2020 | 8675 | 0.08 | Why? |
| Patient Selection | 1 | 2021 | 4560 | 0.08 | Why? |
| China | 7 | 2021 | 50654 | 0.08 | Why? |
| Immunity | 1 | 2017 | 2651 | 0.08 | Why? |
| Autopsy | 1 | 2017 | 3495 | 0.08 | Why? |
| Cross Reactions | 1 | 2017 | 4374 | 0.07 | Why? |
| Chronic Disease | 1 | 2020 | 5139 | 0.07 | Why? |
| Middle Aged | 12 | 2021 | 270681 | 0.07 | Why? |
| Health Services Accessibility | 3 | 2021 | 10697 | 0.07 | Why? |
| Aged | 12 | 2021 | 215776 | 0.07 | Why? |
| Antitubercular Agents | 1 | 2011 | 775 | 0.07 | Why? |
| Mortality | 2 | 2021 | 7132 | 0.07 | Why? |
| London | 1 | 2011 | 2166 | 0.07 | Why? |
| Age Factors | 3 | 2020 | 21039 | 0.07 | Why? |
| Disease Transmission, Infectious | 2 | 2017 | 9044 | 0.07 | Why? |
| Cause of Death | 1 | 2017 | 4823 | 0.06 | Why? |
| Program Evaluation | 1 | 2011 | 1929 | 0.06 | Why? |
| Genetic Predisposition to Disease | 1 | 2017 | 4027 | 0.06 | Why? |
| Risk Assessment | 3 | 2021 | 25439 | 0.06 | Why? |
| Betacoronavirus | 6 | 2020 | 204454 | 0.06 | Why? |
| Policy Making | 2 | 2021 | 829 | 0.06 | Why? |
| Computational Biology | 1 | 2017 | 4514 | 0.06 | Why? |
| Patient Acceptance of Health Care | 1 | 2021 | 5002 | 0.06 | Why? |
| Nigeria | 2 | 2020 | 2292 | 0.06 | Why? |
| Longitudinal Studies | 1 | 2017 | 9893 | 0.06 | Why? |
| Asymptomatic Infections | 1 | 2020 | 7218 | 0.06 | Why? |
| Survival Analysis | 1 | 2015 | 7592 | 0.06 | Why? |
| Aging | 1 | 2018 | 3581 | 0.06 | Why? |
| Cohort Studies | 2 | 2018 | 36005 | 0.05 | Why? |
| Niger | 1 | 2020 | 116 | 0.05 | Why? |
| Northern Ireland | 1 | 2020 | 228 | 0.05 | Why? |
| United States | 4 | 2021 | 46150 | 0.05 | Why? |
| Rabies Vaccines | 1 | 2020 | 106 | 0.05 | Why? |
| Ethical Theory | 1 | 2021 | 126 | 0.05 | Why? |
| Time Factors | 2 | 2021 | 31397 | 0.05 | Why? |
| Diphtheria-Tetanus-acellular Pertussis Vaccines | 1 | 2020 | 91 | 0.05 | Why? |
| India | 1 | 2017 | 11875 | 0.05 | Why? |
| Social Media | 1 | 2021 | 5798 | 0.05 | Why? |
| Basic Reproduction Number | 2 | 2021 | 2676 | 0.05 | Why? |
| Viral Vaccines | 1 | 2020 | 7560 | 0.05 | Why? |
| Hong Kong | 2 | 2018 | 3361 | 0.05 | Why? |
| Philippines | 1 | 2021 | 568 | 0.05 | Why? |
| Surveys and Questionnaires | 4 | 2020 | 43792 | 0.05 | Why? |
| Food Industry | 1 | 2021 | 197 | 0.04 | Why? |
| Telephone | 2 | 2017 | 1705 | 0.04 | Why? |
| Sex Ratio | 1 | 2018 | 69 | 0.04 | Why? |
| Wales | 1 | 2020 | 758 | 0.04 | Why? |
| Georgia | 1 | 2021 | 955 | 0.04 | Why? |
| Kenya | 1 | 2021 | 887 | 0.04 | Why? |
| Socioeconomic Factors | 3 | 2021 | 8495 | 0.04 | Why? |
| Severity of Illness Index | 3 | 2021 | 48226 | 0.04 | Why? |
| Retrospective Studies | 4 | 2019 | 105322 | 0.04 | Why? |
| Neisseria gonorrhoeae | 1 | 2018 | 142 | 0.04 | Why? |
| Chile | 1 | 2021 | 1095 | 0.04 | Why? |
| Influenza, Human | 2 | 2021 | 10779 | 0.04 | Why? |
| Personal Protective Equipment | 1 | 2021 | 15978 | 0.04 | Why? |
| Bias | 1 | 2021 | 1109 | 0.04 | Why? |
| Financing, Government | 1 | 2020 | 434 | 0.04 | Why? |
| Referral and Consultation | 1 | 2011 | 4816 | 0.04 | Why? |
| Hospitalization | 3 | 2021 | 54280 | 0.04 | Why? |
| Hospitals | 3 | 2020 | 11793 | 0.04 | Why? |
| Risk Factors | 3 | 2019 | 71621 | 0.03 | Why? |
| Transportation | 1 | 2021 | 691 | 0.03 | Why? |
| Vomiting | 1 | 2018 | 722 | 0.03 | Why? |
| Government Regulation | 1 | 2020 | 842 | 0.03 | Why? |
| Health Services Research | 1 | 2019 | 756 | 0.03 | Why? |
| Pakistan | 1 | 2021 | 2302 | 0.03 | Why? |
| Clinical Laboratory Techniques | 1 | 2020 | 23402 | 0.03 | Why? |
| Hospital Bed Capacity | 1 | 2020 | 1300 | 0.03 | Why? |
| Adolescent Behavior | 1 | 2018 | 400 | 0.03 | Why? |
| Databases, Factual | 2 | 2018 | 6248 | 0.03 | Why? |
| Health Priorities | 1 | 2021 | 959 | 0.03 | Why? |
| Vaccination Refusal | 1 | 2020 | 831 | 0.03 | Why? |
| Ambulatory Care | 2 | 2020 | 4947 | 0.03 | Why? |
| Mass Screening | 1 | 2011 | 8005 | 0.03 | Why? |
| Decision Support Techniques | 1 | 2018 | 903 | 0.03 | Why? |
| South Africa | 1 | 2021 | 3326 | 0.03 | Why? |
| Antibodies, Neutralizing | 1 | 2017 | 25288 | 0.03 | Why? |
| Disease Eradication | 1 | 2016 | 581 | 0.03 | Why? |
| Polymorphism, Genetic | 1 | 2017 | 1074 | 0.03 | Why? |
| Uncertainty | 1 | 2020 | 1888 | 0.02 | Why? |
| Data Collection | 1 | 2018 | 1769 | 0.02 | Why? |
| Recurrence | 1 | 2018 | 3675 | 0.02 | Why? |
| Child Health | 1 | 2018 | 940 | 0.02 | Why? |
| Interviews as Topic | 1 | 2017 | 1952 | 0.02 | Why? |
| State Medicine | 1 | 2020 | 2847 | 0.02 | Why? |
| Forecasting | 1 | 2020 | 4492 | 0.02 | Why? |
| Diarrhea | 1 | 2018 | 2743 | 0.02 | Why? |
| Comorbidity | 2 | 2021 | 34796 | 0.02 | Why? |
| Research | 1 | 2018 | 2115 | 0.02 | Why? |
| Self Report | 1 | 2017 | 3802 | 0.02 | Why? |
| Genotype | 1 | 2017 | 4697 | 0.02 | Why? |
| Seroepidemiologic Studies | 1 | 2020 | 10017 | 0.02 | Why? |
| Drug Therapy, Combination | 1 | 2018 | 7268 | 0.02 | Why? |
| World Health Organization | 1 | 2018 | 4213 | 0.02 | Why? |
| Antibodies, Viral | 1 | 2017 | 51949 | 0.02 | Why? |
| Intensive Care Units | 2 | 2021 | 29594 | 0.02 | Why? |
| Algorithms | 1 | 2021 | 7346 | 0.02 | Why? |
| Survival Rate | 1 | 2018 | 9206 | 0.02 | Why? |
| Nursing Homes | 1 | 2021 | 4155 | 0.02 | Why? |
| Health Status Disparities | 1 | 2019 | 4072 | 0.01 | Why? |
| Sex Factors | 1 | 2018 | 11014 | 0.01 | Why? |
| Mutation | 1 | 2021 | 12376 | 0.01 | Why? |
| Viral Load | 1 | 2021 | 15850 | 0.01 | Why? |
| T-Lymphocytes | 1 | 2017 | 6670 | 0.01 | Why? |
| Biomedical Research | 1 | 2019 | 5270 | 0.01 | Why? |
| Pregnancy | 1 | 2021 | 23879 | 0.01 | Why? |
| Host-Pathogen Interactions | 1 | 2018 | 11041 | 0.01 | Why? |
| Depression | 1 | 2017 | 14116 | 0.01 | Why? |
| Cross-Sectional Studies | 1 | 2020 | 53120 | 0.01 | Why? |
| Treatment Outcome | 1 | 2018 | 51732 | 0.01 | Why? |
| Anxiety | 1 | 2017 | 17311 | 0.01 | Why? |